丁酸梭菌
微生物学
益生菌
失调
抗生素
生物
病菌
抗生素耐药性
殖民抵抗
艰难梭菌
细菌
微生物群
生物信息学
遗传学
作者
Tadashi Ariyoshi,Mao Hagihara,Motomichi Takahashi,Hiroshige Mikamo
出处
期刊:Biomedicines
[MDPI AG]
日期:2022-02-18
卷期号:10 (2): 483-483
被引量:24
标识
DOI:10.3390/biomedicines10020483
摘要
Clostridium butyricum is a human commensal bacterium with beneficial effects including butyrate production, spore formation, increasing levels of beneficial bacteria, and inhibition of pathogenic bacteria. Owing to its preventive and ameliorative effects on gastrointestinal infections, C. butyricum MIYAIRI 588 (CBM 588) has been used as a probiotic in clinical and veterinary medicine for decades. This review summarizes the effects of C. butyricum, including CBM 588, on bacterial gastrointestinal infections. Further, the characteristics of the causative bacteria, examples of clinical and veterinary use, and mechanisms exploited in basic research are presented. C. butyricum is widely effective against Clostoridioides difficile, the causative pathogen of nosocomial infections; Helicobacter pylori, the causative pathogen of gastric cancer; and antibiotic-resistant Escherichia coli. Accordingly, its mechanism is gradually being elucidated. As C. butyricum is effective against gastrointestinal infections caused by antibiotics-induced dysbiosis, it can inhibit the transmission of antibiotic-resistant genes and maintain homeostasis of the gut microbiome. Altogether, C. butyricum is expected to be one of the antimicrobial-resistance (AMR) countermeasures for the One-health approach.
科研通智能强力驱动
Strongly Powered by AbleSci AI